Concepedia

Srinivas Kodali

SK

Statistics

Publications

16

Citations

2.3K

H-Index

14

Active since

2001

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Pfizer (United States)

Srinivas Kodali is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in microbiology, life sciences, and drug discovery.

ORCID

Publications per year

2001–2025

16

Publications

16

Platensimycin is a selective FabF inhibitor with potent antibiotic properties

Jun Wang, S.M. Soisson, Katherine Young et al. · Nature · 2006 · 815 citations

, , +9

Discovery of platencin, a dual FabF and FabH inhibitor with <i>in vivo</i> antibiotic properties

Jun Wang, Srinivas Kodali, Sang Ho Lee et al. · Proceedings of the National Academy of Sciences · 2007 · 380 citations · Full text

, , +14

Discovery of FabH/FabF Inhibitors from Natural Products

Katherine Young, Hiranthi Jayasuriya, John G. Ondeyka et al. · Antimicrobial Agents and Chemotherapy · 2006 · 200 citations · Full text

, , +14

Discovery of a Small Molecule That Inhibits Cell Division by Blocking FtsZ, a Novel Therapeutic Target of Antibiotics

Jun Wang, Andrew Galgoci, Srinivas Kodali et al. · Journal of Biological Chemistry · 2003 · 199 citations · Full text

, , +15

A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization

Ed T. Buurman, Yekaterina Timofeyeva, Jianxin Gu et al. · The Journal of Infectious Diseases · 2019 · 113 citations · Full text

, , +17

1–5 of 16